The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

BACKGROUND: There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Alexandra J, Morris, Susan, Ulaszewska, Marta, Powers, Claire, Kailath, Reshma, Bissett, Cameron, Truby, Adam, Thakur, Nazia, Newman, Joseph, Allen, Elizabeth R, Rudiansyah, Indra, Liu, Chang, Dejnirattisai, Wanwisa, Mongkolsapaya, Juthathip, Davies, Hannah, Donnellan, Francesca R, Pulido, David, Peacock, Thomas P., Barclay, Wendy S., Bright, Helen, Ren, Kuishu, Screaton, Gavin, McTamney, Patrick, Bailey, Dalan, Gilbert, Sarah C, Lambe, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881183/
https://www.ncbi.nlm.nih.gov/pubmed/35228013
http://dx.doi.org/10.1016/j.ebiom.2022.103902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881183/
https://www.ncbi.nlm.nih.gov/pubmed/35228013
http://dx.doi.org/10.1016/j.ebiom.2022.103902

Ejemplares similares